The Challenge
A national food and beverage group operating across the UAE had engaged us on a managed FP&A retainer — monthly variance analysis, budget tracking, and board reporting. Month three of the engagement was supposed to be routine.
The company's primary product line included a range of nutritional supplements sold through pharmacies and health retailers across the GCC. The management accounts showed a slight improvement in gross margin — unusual, but not alarming on its face.
Nobody had flagged anything. The operations team assumed procurement had found a better supplier deal. Finance assumed operations knew what they were doing.
Our Process
Standard variance analysis on cost of goods sold surfaced an anomaly: raw material costs had declined 8.3% in the period, but finished goods output volumes were flat. That gap — lower input cost, same output — required an explanation.
Input-to-output reconciliation. We cross-referenced production records with procurement invoices and the approved bill of materials. A key ingredient — one of the active compounds in the supplement formula — had been substituted by the operations team with an alternative supplier's variant. The two compounds were similar but not equivalent under UAE food authority regulations.
Regulatory impact assessment. We escalated immediately to the CFO. Working with an external regulatory advisor, we identified that the substituted compound had a different classification under UAE Ministry of Health guidelines — meaning the product's existing licence did not cover its current formulation. The company had been selling a technically unlicensed formulation for six weeks.
Crisis response coordination. We prepared the financial impact analysis for the board: regulatory penalty exposure, voluntary recall cost modelling, and a remediation path that minimised disruption to the distribution network.
Key Outcome
The finding was uncomfortable — but the alternative was far worse. Had the issue been identified by a regulator rather than internally, the company would have faced compulsory recall, potential licence suspension, and fines that our analysis estimated at $2.1M under worst-case enforcement scenarios.
The early detection allowed the company to self-report, initiate a controlled product withdrawal, and engage regulators proactively. The regulatory response was substantially more favourable as a result.
Results
- ·$2.1M in estimated regulatory penalty exposure neutralised through early detection and self-reporting
- ·Controlled product withdrawal completed within 10 days; shelf restocking with compliant formulation within 28 days
- ·No licence suspension — regulatory authority accepted the company's remediation plan and compliance roadmap
- ·Internal control gap closed: formulation changes now require sign-off from finance and legal before procurement can substitute any classified ingredient
- ·Ongoing engagement: we now conduct quarterly supply chain variance reviews as a standing control for the group